2022
Coagulation factor V is a T-cell inhibitor expressed by leukocytes in COVID-19
Wang J, Kotagiri P, Lyons PA, Al-Lamki RS, Mescia F, Bergamaschi L, Turner L, Morgan MD, Calero-Nieto FJ, Bach K, Mende N, Wilson NK, Watts ER, Collaboration C, Maxwell PH, Chinnery PF, Kingston N, Papadia S, Stirrups KE, Walker N, Gupta RK, Menon DK, Allinson K, Aitken SJ, Toshner M, Weekes MP, Nathan JA, Walmsley SR, Ouwehand WH, Kasanicki M, Göttgens B, Marioni JC, Smith KGC, Pober JS, Bradley JR. Coagulation factor V is a T-cell inhibitor expressed by leukocytes in COVID-19. IScience 2022, 25: 103971. PMID: 35224470, PMCID: PMC8863325, DOI: 10.1016/j.isci.2022.103971.Peer-Reviewed Original ResearchFactor VSuppress T-cell proliferationCOVID-19 lung diseasePeripheral blood mononuclear cellsCOVID-19Severe COVID-19Blood mononuclear cellsT-cell lymphopeniaT-cell inhibitorsT cell proliferationAdaptive immune systemHospitalized patientsRegulatory cellsLung diseaseMononuclear cellsDisease correlateCoagulation factor VImmune systemLeukocytesNeutrophilsFV expressionFactor VaLymphopeniaCellsPatients
2009
Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases
Aitken S, Thomas J, Langdon S, Harrison D, Faratian D. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Annals Of Oncology 2009, 21: 1254-1261. PMID: 19858088, DOI: 10.1093/annonc/mdp427.Peer-Reviewed Original ResearchConceptsNodal diseaseReceptor statusPrimary tumorAdjuvant therapyHER2 expressionReceptor expressionInvasive primary breast carcinomasPaired lymph nodeQuantitative receptor expressionPrimary breast carcinomaPrimary breast cancerResistance to therapyExpression of molecular markersNodal metastasisBreast carcinomaLymph nodesTherapeutic resistanceBreast cancerQuantitative immunofluorescenceClinical trialsTumorImmunohistochemistryTherapyPatientsMolecular phenotypes